These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach. Emerson SS Biometrics; 1995 Sep; 51(3):1152-62. PubMed ID: 7548699 [TBL] [Abstract][Full Text] [Related]
44. Group sequential designs for monitoring survival probabilities. Lin DY; Shen L; Ying Z; Breslow NE Biometrics; 1996 Sep; 52(3):1033-41. PubMed ID: 8805766 [TBL] [Abstract][Full Text] [Related]
45. Guidelines for monitoring efficacy and toxicity responses in clinical trials. Cook RJ; Farewell VT Biometrics; 1994 Dec; 50(4):1146-52. PubMed ID: 7786995 [TBL] [Abstract][Full Text] [Related]
46. Sequential monitoring of clinical trials with multiple survival endpoints. Williams PL Stat Med; 1996 Nov 15-30; 15(21-22):2341-57; discussion 2367-70. PubMed ID: 8931205 [TBL] [Abstract][Full Text] [Related]
47. A note on P-values under group sequential testing and nonproportional hazards. Gillen DL; Emerson SS Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703 [TBL] [Abstract][Full Text] [Related]
48. Selection designs for pilot studies based on survival. Liu PY; Dahlberg S; Crowley J Biometrics; 1993 Jun; 49(2):391-8. PubMed ID: 8369375 [TBL] [Abstract][Full Text] [Related]
49. Group sequential t-test for clinical trials with small sample sizes across stages. Shao J; Feng H Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814 [TBL] [Abstract][Full Text] [Related]
50. Optimal conditional error functions for the control of conditional power. Brannath W; Bauer P Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294 [TBL] [Abstract][Full Text] [Related]
51. Random effects probit and logistic regression models for three-level data. Gibbons RD; Hedeker D Biometrics; 1997 Dec; 53(4):1527-37. PubMed ID: 9423267 [TBL] [Abstract][Full Text] [Related]
52. A review of methods for futility stopping based on conditional power. Lachin JM Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130 [TBL] [Abstract][Full Text] [Related]
53. The performance of the O'Brien-Fleming multiple testing procedure in the presence of intraclass correlation. Lui KJ Biometrics; 1994 Mar; 50(1):232-6. PubMed ID: 8086606 [TBL] [Abstract][Full Text] [Related]
55. Confidence intervals for a normal mean following a group sequential test. Chang MN Biometrics; 1989 Mar; 45(1):247-54. PubMed ID: 2720054 [TBL] [Abstract][Full Text] [Related]
56. Fitting spending functions. Anderson KM; Clark JB Stat Med; 2010 Feb; 29(3):321-7. PubMed ID: 19842091 [TBL] [Abstract][Full Text] [Related]
57. A comment on the importance of numerical evaluation of analytic solutions involving approximations. Overall JE; Starbuck RR; Doyle SR J Biopharm Stat; 1994 Jul; 4(2):217-22. PubMed ID: 7951276 [TBL] [Abstract][Full Text] [Related]
58. Some extensions to a new approach for interim analysis in clinical trials. Falissard B; Lellouch J Stat Med; 1991 Jun; 10(6):949-55; discussion 956-7. PubMed ID: 1876784 [TBL] [Abstract][Full Text] [Related]
59. On group sequential procedures under variance heterogeneity. Hussein A; Carriere KC Stat Methods Med Res; 2005 Apr; 14(2):121-8. PubMed ID: 15807147 [TBL] [Abstract][Full Text] [Related]
60. An overview of group sequential methods in longitudinal clinical trials. Spiessens B; Lesaffre E; Verbeke G; Kim K; DeMets DL Stat Methods Med Res; 2000 Oct; 9(5):497-515. PubMed ID: 11191262 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]